J. B. Chemicals & Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
J. B. Chemicals & Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 19.4% bzw. 12.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 19.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 22.1% betragen.
Wichtige Informationen
19.4%
Wachstumsrate der Gewinne
19.4%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 17.9% |
| Wachstumsrate der Einnahmen | 12.8% |
| Zukünftige Eigenkapitalrendite | 22.1% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 09 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Nov 09
J. B. Chemicals & Pharmaceuticals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 11J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Feb 09Recent updates
We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt
Nov 27J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Nov 09J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) Business Is Yet to Catch Up With Its Share Price
Sep 24Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation
Aug 15J. B. Chemicals & Pharmaceuticals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 11These 4 Measures Indicate That J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Using Debt Reasonably Well
Jun 28J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Apr 19J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Feb 09J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Dec 22We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt
Nov 29J. B. Chemicals & Pharmaceuticals' (NSE:JBCHEPHARM) Dividend Will Be Increased To ₹9.25
Aug 03J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Due To Pay A Dividend Of ₹8.50
Feb 11Is J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Using Too Much Debt?
Dec 03A Look At The Intrinsic Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
Sep 21J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Seems To Use Debt Quite Sensibly
Aug 03Estimating The Fair Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
Jun 15Does J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Have A Healthy Balance Sheet?
Mar 29J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Has Re-Affirmed Its Dividend Of ₹8.50
Feb 16Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2027 | 51,190 | 9,990 | 6,916 | 10,684 | 12 |
| 3/31/2026 | 45,566 | 8,601 | 7,687 | 9,249 | 14 |
| 3/31/2025 | 40,336 | 7,074 | 6,517 | 7,863 | 14 |
| 9/30/2024 | 37,113 | 6,111 | 5,317 | 7,451 | N/A |
| 6/30/2024 | 35,924 | 5,871 | N/A | N/A | N/A |
| 3/31/2024 | 34,842 | 5,526 | 5,316 | 7,890 | N/A |
| 12/31/2023 | 33,848 | 5,141 | N/A | N/A | N/A |
| 9/30/2023 | 33,330 | 4,866 | 2,888 | 7,680 | N/A |
| 6/30/2023 | 32,607 | 4,471 | N/A | N/A | N/A |
| 3/31/2023 | 31,493 | 4,098 | -1,291 | 6,286 | N/A |
| 12/31/2022 | 30,115 | 4,071 | N/A | N/A | N/A |
| 9/30/2022 | 28,195 | 3,848 | -7,379 | 3,122 | N/A |
| 6/30/2022 | 26,031 | 3,715 | N/A | N/A | N/A |
| 3/31/2022 | 24,242 | 3,854 | -5,367 | 1,701 | N/A |
| 12/31/2021 | 23,281 | 4,011 | N/A | N/A | N/A |
| 9/30/2021 | 22,757 | 4,713 | 3,154 | 3,745 | N/A |
| 6/30/2021 | 21,262 | 4,474 | N/A | N/A | N/A |
| 3/31/2021 | 20,425 | 4,480 | 2,670 | 3,148 | N/A |
| 12/31/2020 | 19,576 | 3,975 | N/A | N/A | N/A |
| 9/30/2020 | 18,381 | 3,097 | 1,178 | 1,786 | N/A |
| 6/30/2020 | 18,509 | 3,295 | N/A | N/A | N/A |
| 3/31/2020 | 17,747 | 2,720 | 2,028 | 2,757 | N/A |
| 12/31/2019 | 17,501 | 2,686 | N/A | N/A | N/A |
| 9/30/2019 | 17,035 | 2,521 | 2,148 | 2,749 | N/A |
| 6/30/2019 | 16,824 | 2,098 | N/A | N/A | N/A |
| 3/31/2019 | 16,432 | 1,935 | 1,452 | 1,943 | N/A |
| 3/31/2018 | 14,084 | 1,383 | N/A | 1,229 | N/A |
| 3/31/2017 | 13,443 | 1,841 | N/A | 2,011 | N/A |
| 3/31/2016 | 12,104 | 1,625 | N/A | 1,404 | N/A |
| 3/31/2015 | 11,442 | 1,004 | N/A | 1,267 | N/A |
| 3/31/2014 | 10,219 | 615 | N/A | -140 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: JBCHEPHARMDas prognostizierte Gewinnwachstum (19.4% pro Jahr) liegt über der Sparquote (6.7%).
Ertrag vs. Markt: JBCHEPHARMDie Erträge des Unternehmens (19.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (17.9% pro Jahr).
Hohe Wachstumserträge: JBCHEPHARMDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: JBCHEPHARMDie Einnahmen des Unternehmens (12.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (10.4% pro Jahr).
Hohe Wachstumseinnahmen: JBCHEPHARMDie Einnahmen des Unternehmens (12.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: JBCHEPHARMDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (22.1%)